Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences, and Collaborative Innovation Center for Brain Science , Chongqing University , Chongqing 401331 , China.
Innovative Drug Research and Bioinformatics Group, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou 310058 , China.
ACS Chem Neurosci. 2018 Jun 20;9(6):1492-1502. doi: 10.1021/acschemneuro.8b00059. Epub 2018 Mar 16.
Metabotropic glutamate receptor 5 (mGlu) plays a key role in synaptic information storage and memory, which is a well-known target for a variety of psychiatric and neurodegenerative disorders. In recent years, the increasing efforts have been focused on the design of allosteric modulators, and the negative allosteric modulators (NAMs) are the front-runners. Recently, the architecture of the transmembrane (TM) domain of mGlu receptor has been determined by crystallographic experiment. However, it has been not well understood how the pharmacophores of NAMs accommodated into the allosteric binding site. In this study, molecular dynamics (MD) simulations were performed on mGlu receptor bound with NAMs in preclinical or clinical development to shed light on this issue. In order to identify the key residues, the binding free energies as well as per-residue contributions for NAMs binding to mGlu receptor were calculated. Subsequently, the in silico site-directed mutagenesis of the key residues was performed to verify the accuracy of simulation models. As a result, the shared common features of the studied 5 clinically important NAMs (mavoglurant, dipraglurant, basimglurant, STX107, and fenobam) interacting with 11 residues in allosteric site were obtained. This comprehensive study presented a better understanding of mGlu receptor NAMs binding mechanism, which would be further used as a useful framework to assess and discover novel lead scaffolds for NAMs.
代谢型谷氨酸受体 5 (mGlu) 在突触信息存储和记忆中发挥着关键作用,这是各种精神和神经退行性疾病的众所周知的靶点。近年来,人们越来越关注变构调节剂的设计,负变构调节剂 (NAMs) 是领先者。最近,通过晶体学实验确定了 mGlu 受体跨膜 (TM) 域的结构。然而,人们对 NAMs 的药效团如何适应变构结合位点还不太了解。在这项研究中,对处于临床前或临床开发阶段的与 NAMs 结合的 mGlu 受体进行了分子动力学 (MD) 模拟,以阐明这个问题。为了确定关键残基,计算了 NAMs 与 mGlu 受体结合的结合自由能和每个残基的贡献。随后,对关键残基进行了计算机模拟的定点诱变,以验证模拟模型的准确性。结果,获得了与变构位点 11 个残基相互作用的 5 种临床重要的 NAMs(mavoglurant、dipraglurant、basimglurant、STX107 和 fenobam)的共同特征。这项综合研究更好地了解了 mGlu 受体 NAMs 的结合机制,这将进一步用作评估和发现新型 NAMs 先导骨架的有用框架。